| Literature DB >> 26497333 |
Sevil Korkmaz-Icöz1, Ayhan Atmanli2, Tamás Radovits3, Shiliang Li2, Peter Hegedüs2, Mihály Ruppert2,3, Paige Brlecic2, Yutaka Yoshikawa4, Hiroyuki Yasui4, Matthias Karck2, Gábor Szabó2.
Abstract
We recently demonstrated that the pre-treatment of rats with zinc and acetylsalicylic acid complex in the form of bis(aspirinato)zinc(II) [Zn(ASA)2] is superior to acetylsalicylic acid in protecting the heart from acute myocardial ischemia. Herein, we hypothesized that Zn(ASA)2 treatment after the onset of an acute myocardial injury could protect the heart. The rats were treated with a vehicle or Zn(ASA)2 after an isoproterenol injection. Isoproterenol-induced cardiac damage [inflammatory infiltration into myocardial tissue, DNA-strand breakage evidenced by TUNEL-assay, increased 11-dehydro thromboxane (TX)B2-levels, elevated ST-segment, widened QRS complex and prolonged QT-interval] was prevented by the Zn(ASA)2 treatment. In isoproterenol-treated rats, load-independent left ventricular contractility parameters were significantly improved after Zn(ASA)2. Furthermore, Zn(ASA)2 significantly increased the myocardial mRNA-expression of superoxide dismutase-1, glutathione peroxidase-4 and decreased the level of Na(+)/K(+)/ATPase. Postconditioning with Zn(ASA)2 protects the heart from acute myocardial ischemia. Its mechanisms of action might involve inhibition of pro-inflammatory prostanoids and upregulation of antioxidant enzymes.Entities:
Keywords: Isoproterenol; Myocardial ischemia; Zinc complex of acetylsalicylic acid
Mesh:
Substances:
Year: 2015 PMID: 26497333 DOI: 10.1007/s12576-015-0403-6
Source DB: PubMed Journal: J Physiol Sci ISSN: 1880-6546 Impact factor: 2.781